logo-loader
RNS
Byotrol

Byotrol PLC - Director Dealing

RNS Number : 0214J
Byotrol PLC
02 April 2024
 

Logo, company name Description automatically generated

 

 



Byotrol Plc

("Byotrol" or the "Company")

 

Director Dealing

 

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, announces that, on 2nd April 2024, David Traynor, Interim CEO of the Company, purchased a total of 2,808,326 ordinary shares of 0.25p each ("Ordinary Shares") at an average price of 0.134p per Ordinary Share (the "Purchase").

 

Following the Purchase, Mr. Traynor's beneficial holding is 12,743,623 Ordinary Shares, representing 2.8% of the total voting rights of the Company. As announced on 28 July 2022, Mr. Traynor subscribed for convertible loan notes in the Company, which if converted would represent an additional 0.34% of the total voting rights of the Company.

 

 

For further information contact:

 

Byotrol Plc


Dr Trevor Francis, Non- Executive Chairman

+44 (0)1925 742 000

David Traynor, Interim Chief Executive Officer

Chris Sedwell, Chief Financial Officer

 




Cavendish Capital Markets Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash/George Dollemore - Corporate Finance

Nigel Birks/Harriet Ward - ECM






Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon                                          

 

byotrol@flagstaffcomms.com

 

 

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the animal and human healthare, industrial, institutional and consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, go to byotrol.com

 

 

The Notification of Dealing Form set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Traynor

2.               

Reason for the Notification

a)

Position/status

Interim Chief Executive Officer

b)

Initial notification/Amendment

Initial Notification

3.   

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol plc

b)

LEI

213800AJMTSTIPA59A34

4.   

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 0.25 pence per share

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

0.134p

2,808,326

d)

Aggregated information:

·Aggregated volume

· Price

 

See 4c) above

e)

Date of the transaction

2 April 2024

f)

Place of the transaction

AIM, London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGGDDZDGDZM
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read